These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36065929)

  • 1. Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
    Rinaldi D; Alborghetti M; Bianchini E; Sforza M; Galli S; Pontieri FE
    Curr Neuropharmacol; 2023; 21(5):1214-1223. PubMed ID: 36065929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
    Alborghetti M; Nicoletti F
    Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
    Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function.
    Murakami H; Okumura M; Ozawa M; Mimori M; Maku T; Shiraishi T; Kitagawa T; Takatsu H; Sato T; Komatsu T; Sakai K; Umehara T; Omoto S; Mitsumura H; Iguchi Y
    Neurol Sci; 2023 Mar; 44(3):913-918. PubMed ID: 36376554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
    Jost WH
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
    Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.
    Chew ZX; Lim CL; Ng KY; Chye SM; Ling APK; Koh RY
    CNS Neurol Disord Drug Targets; 2023; 22(3):329-352. PubMed ID: 34970960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Müller T; Riederer P; Grünblatt E
    J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
    Tan YY; Jenner P; Chen SD
    J Parkinsons Dis; 2022; 12(2):477-493. PubMed ID: 34957948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
    Riederer P; Müller T
    J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
    Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
    Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
    Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
    Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.